These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Ogasahara S; Nishikawa Y; Yorifuji S; Soga F; Nakamura Y; Takahashi M; Hashimoto S; Kono N; Tarui S Neurology; 1986 Jan; 36(1):45-53. PubMed ID: 3941783 [TBL] [Abstract][Full Text] [Related]
5. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Ogasahara S; Yorifuji S; Nishikawa Y; Takahashi M; Wada K; Hazama T; Nakamura Y; Hashimoto S; Kono N; Tarui S Neurology; 1985 Mar; 35(3):372-7. PubMed ID: 3974895 [TBL] [Abstract][Full Text] [Related]
6. Progressive cytochrome c oxidase deficiency in a case of Kearns-Sayre syndrome: morphological, immunological, and biochemical studies in muscle biopsies and autopsy tissues. Bresolin N; Moggio M; Bet L; Gallanti A; Prelle A; Nobile-Orazio E; Adobbati L; Ferrante C; Pellegrini G; Scarlato G Ann Neurol; 1987 Jun; 21(6):564-72. PubMed ID: 3037990 [TBL] [Abstract][Full Text] [Related]
7. The influence of Coenzyme Q10 on total serum calcium concentration in two patients with Kearns-Sayre Syndrome and hypoparathyroidism. Papadimitriou A; Hadjigeorgiou GM; Divari R; Papagalanis N; Comi G; Bresolin N Neuromuscul Disord; 1996 Jan; 6(1):49-53. PubMed ID: 8845718 [TBL] [Abstract][Full Text] [Related]
8. Improvement of Kearns-Sayre syndrome with controlled carbohydrate intake and coenzyme Q10 therapy. Berio A; Piazzi A Ophthalmologica; 1994; 208(6):342-3. PubMed ID: 7845654 [No Abstract] [Full Text] [Related]
9. Kearns-Sayre syndrome: biochemical studies of mitochondrial metabolism. Martens ME; Peterson PL; Lee CP; Nigro MA; Hart Z; Glasberg M; Hatfield JS; Chang CH Ann Neurol; 1988 Nov; 24(5):630-7. PubMed ID: 2849368 [TBL] [Abstract][Full Text] [Related]
10. [Treatment with ubiquinone in Kearns-Sayre syndrome. Improvement in ocular motility and visual evoked potentials]. Calatayud MT; Díaz-Castroverde AG; Solar M; Díaz M; Uría DF; Martínez C; González C; Méndez C Neurologia; 1992 Nov; 7(9):266-9. PubMed ID: 1445712 [TBL] [Abstract][Full Text] [Related]
12. [Clinical, morphological and biochemical findings in the Kearns-Sayre syndrome]. Hammerstein W; Mortier W; Noack EA; Frenzel H; Liebert UG; Toyka K; Horstkotte D; Bischof G; Weber U Fortschr Ophthalmol; 1983; 80(3):193-200. PubMed ID: 6629235 [No Abstract] [Full Text] [Related]
13. Reversible ophthalmoplegia in CPEO. Dunlop IS; Dunlop P Aust N Z J Ophthalmol; 1995 Aug; 23(3):231-4. PubMed ID: 8534451 [TBL] [Abstract][Full Text] [Related]
14. [Ophthalmoplegia plus and ragged red fibers. Description of a case manifested in childhood]. De Langlade E; Corazza G; Minetti C; Bado M; Venzano V; Chiossi FM Minerva Pediatr; 1983 Nov; 35(22):1117-23. PubMed ID: 6672599 [No Abstract] [Full Text] [Related]
15. [Mitochondrial encephalomyopathy. 2 cases with Kearns-Sayre syndrome]. Sánchez JC; Guisado F; Pastor E; Maestre J; Vilches R; García T Neurologia; 1986; 1(4):150-3. PubMed ID: 3274110 [No Abstract] [Full Text] [Related]
16. Abnormal evoked potentials of Kearns-Sayre syndrome. Nakamura Y; Takahashi M; Kitaguchi M; Yorifuji S; Nishikawa Y; Imaoka H; Tarui S Electromyogr Clin Neurophysiol; 1995 Oct; 35(6):365-70. PubMed ID: 8785934 [TBL] [Abstract][Full Text] [Related]
17. [Ophthalmoplegia plus and the Kearns-Sayre syndrome]. Pellissier JF; Gastaut JL; Serratrice G; Toga M Rev Otoneuroophtalmol; 1983; 55(1):57-66. PubMed ID: 6351225 [No Abstract] [Full Text] [Related]